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Positive and negative effects of antipsychotic medication: an international 
online survey of 832 recipients 
 
Abstract 
Background: Antipsychotic medication is currently the treatment of choice for psychosis, but 
few studies directly survey the first hand experience of recipients. 
Objectives: To ascertain the experiences and opinions of users of an international sample of 
antipsychotic drugs regarding positive and negative effects. 
Method: An online direct-to-consumer questionnaire was completed by 832 users of 
antipsychotics, from 30 countries – predominantly USA, UK and Australia. This is the largest 
such sample to date. 
Results: Over half (56%) thought the drugs reduced the problems they were prescribed for, 
but 27% thought they made them worse.  Slightly less people found the drugs generally 
‘Helpful’ (41%) than found them ‘Unhelpful’ (43%).  While 35% reported that their ‘quality 
of life’ was ‘improved’, 54% reported that it was made ‘worse’. The average number of 
adverse effects reported was 11, with an average of five at the ‘severe’ level. Fourteen effects 
were reported by 57% or more participants, most commonly: ‘Drowsiness, feeling tired, 
sedation’ (92%), ‘Loss of motivation’ (86%), ‘Slowed thoughts’ (86%), and ‘Emotional 
numbing’ (85%). Suicidality was reported to be a side effect by 58%. Older people reported 
particularly poor outcomes and high levels of adverse effects. Duration of treatment was 
unrelated to positive outcomes but significantly related to negative outcomes. Most 
respondents (70%) had tried to stop taking the drugs. The most common reasons people 
wanted to stop were the side effects (64%) and worries about long-term physical health 
(52%). Most (70%) did not recall being told anything at all about side effects. 
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Conclusions Clinical implications are discussed, with a particular focus on the principles of 
informed consent, and involving patients in decision making about their own lives. 
 
Keywords: Antipsychotic drugs, psychosis, side effects, suicidality, quality of life, sedation, 
informed consent 
 
1. INTRODUCTION 
Antipsychotic drugs are the cornerstone of treatment for people diagnosed with 
‘schizophrenia’ spectrum disorders, and are increasingly used for other problems and with 
adolescents, old people and prisoners [1].  Guidelines from governments [2] and psychiatrists 
[3] strongly recommend antipsychotics. Recently, however, studies suggest that claims about 
their efficacy, and safety, have been exaggerated [4-9]. 
A review of 38 trials of ‘atypical’ (‘second generation’) antipsychotics drugs found that 
symptom reduction did not meet the threshold for minimal clinical improvement, and that 
17% of those taking antipsychotics long term relapsed, compared to 39% of those taking 
placebo, meaning that only 22% benefitted from the medication [4]. Another review, of 120 
studies, confirmed that antipsychotics are associated with less than minimal global 
improvement [5]. A Cochrane review concluded that ‘Data are too limited to assess outcomes 
from initial antipsychotic medication treatment for individuals with an early episode of 
schizophrenia’ [6]. A recent meta-analysis of 167 double-blind randomized controlled trials 
found that 23% had a ‘good’ response in the antipsychotic group vs 14% on placebos and that 
industry sponsored studies produced significantly more positive results [7].  
 Five evaluations of psychosocial treatments combined with postponement of 
antipsychotics all demonstrated advantages compared to immediate medication treatment [8]. 
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A recent study found no difference in symptom severity between those taking and not taking 
antipsychotics, and that the non-medicated people had higher level social functioning [9]. 
 
1.1 Adverse Effects 
Amongst the many adverse effects of first generation, or ‘typical’ antipsychotics, the most 
disturbing was Tardive Dyskinesia, which involves uncontrollable movements of face, hands 
and feet [2]. The ‘atypicals’ were marketed, in the 1990s, largely on the claim that they did 
not cause Tardive Dyskinesia [10], which was untrue [2, 10, 11]. Moreover, the newer drugs 
had other adverse effects: cardiovascular effects, metabolic effects, sexual dysfunction, 
sedation, dizziness, akathisia, dry mouth, reduced brain volume, and shortened life span [2, 
12-15]. These effects contribute to findings that about half of antipsychotic recipients do not 
comply with treatment [16], and about three quarters stop antipsychotics within 18 months 
[17]. 
 
1.2 First Person Experiences 
Most of these studies, of efficacy and safety, involve quantitative methods, including 
RCTs, often of short duration [12]. Less attention has been given to the ‘real-life’ experiences 
of people who take the drugs. Some of the few studies of self-reports seem less interested in 
the experiences per se than on predicting ‘non-compliance’ [18, 19]. A few studies have 
looked at the process of withdrawing [20-22].  Some small but valuable studies have focussed 
on adverse effects [23-26].  For example ten Australian antipsychotic users reported an 
average of six side effects, with ‘a major disruptive impact on their lives’ [27]. The most 
frequent was sedation, described as a ‘zombie'‐like state. A recent study of 20 British 
antipsychotic users [28] revealed a range of attitudes to antipsychotics, but ‘They commonly 
experienced their prescribing psychiatrist as not sufficiently acknowledging the negative 
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impacts of medication on life quality and physical health concerns.’ Even 69 British people 
who mostly found antipsychotics helpful, did not feel involved in treatment decisions and had 
not been warned about side effects or offered alternative treatments [29]. 
      The adverse effects most frequently reported by 205 people used in the development of 
the Australian My Medicines and Me questionnaire [30] were: ‘felt tired’ (77%) and ‘had 
difficulty waking up’ (59%). The recently published Maudsley Side Effects measure for 
Antipsychotics included service users in its development [31]. Fifty three side effects were 
identified. The mean number of these effects reported by 93 recipients was 21, most 
frequently ‘feel tired’ (77%) and ‘put weight on’ (70%). The most common adverse effects 
reported by 439 users of an Internet site were sedation, cognitive impairment, emotional 
flattening and loss of interest [32].  
 
1.3 Aims 
The only large scale surveys of psychiatric drug recipients have been for antidepressants [33-
36].  The current study replicated these surveys with users of antipsychotics, in order to assess 
the ‘real life’ experiences of the largest sample to date. 
 
 
2. METHODS 
Approval for the study was granted by the Swinburne Human Research Ethics Committee, at 
the Swinburne University of Technology in Melbourne, Australia. 
2.1 Instrument 
‘The Experiences of Antidepressant and Antipsychotic Medication Survey’, developed for 
this study, was based on the New Zealand ‘Views on Antidepressants’ questionnaire [33, 36].  
Questions relating to psychosis and antipsychotics were added, based largely on the research 
summarized above. This online questionnaire used Qualtrics survey software, and generated 
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quantitative (yes/no and multiple-choice questions) and qualitative data (open-ended 
questions) about: the prescribing experience, the positive and negative effects of medications, 
causal beliefs about psychosis/depression, alternative treatments, experiences of withdrawing 
from the medications, and demographics.  
     This paper reports the positive and adverse outcomes of the antipsychotics section, and 
responses to the question (in a Section entitled ‘When you were first prescribed antipsychotic 
medication’) ‘Did the doctor inform you of any possible side effects?’ (Yes/No) and ‘If Yes, 
what side effects were mentioned?’ 
 
2.2 Participants 
Of the 2,346 people who responded 1,067 reported that they had taken antipsychotics. 
However, 104 failed to tick ‘Yes’ for the item confirming they met three criteria: ‘I have been 
taking or have previously taken antipsychotic medication continuously for at least one 
month’; ‘I am aged 18 or older’; and ‘I am not currently compulsorily detained in a 
psychiatric hospital’. Among the remaining 963 responses, 51 emanated from the same 
Internet Protocol (IP) address as another response, indicating use of the same computer. Of 
these 51, 23 were deemed a repeat response by the same person (based on identical 
demographics or similar responses). Of the remaining 938, 27 responded to ‘What is the 
name of your current or most recent antipsychotic medication?’ with a drug that is not an 
antipsychotic. Of the remaining 911, 79 completed only the demographics section, leaving 
832 for analysis.  
Of these 832, 98 (11.8%) were recruited via an Australian online research company (GMI 
Research) and the remaining 734 via advertisements on social media and snowball sampling. 
 
2.3 Data Analysis 
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A Total Adverse Effects (TAE) score was calculated by combining the scores (0-3) of the 
16 effects, producing a range of 0 to 48. Spearman Rank Order Correlation Coefficients (rho) 
were used to test for relationships between dimensional variables, e.g. age and likert scale 
measures of positive and negative effects. Independent sample, two-tailed t-tests were used to 
explore differences between mean scores in relation to gender and whether or not participants 
had been informed about adverse effects. The level of significance was set at p < .05, except 
for analyses of the 16 adverse effects for which the p < .01 level was used because of the high 
number of tests and the risk of false positives. 
 
3. RESULTS 
3.1 Sample Characteristics 
Table 1 summarises the characteristics of the 832 respondents, from 30 countries. 
 
3.2 Efficacy 
Tables 1 and 2 about here 
Table 2 summarises the self-reported efficacy of the antipsychotics, in response to three 
questions. There was no difference, on any of these efficacy variables, between those who 
had only taken antipsychotics and those who had also taken antidepressants. Gender was 
unrelated to the three variables. Older age was correlated with negative outcomes for two of 
the three: Helpful - rho = .08 (p < .05); and Improved Quality of Life – rho = .10 (p < .01). 
Length of time taking antipsychotics was unrelated to Reduction of problems or Quality of 
Life, but was related to being less Helpful (rho = .10, p < .001). 
 
3.3 Adverse Effects 
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The mean number of adverse effects was 11.2 (sd = 3.5), with an average of 5.0 (sd = 4.0) 
reported as ‘severe’.  Nearly two thirds of respondents (64.3%) reported ten or more effects. 
Table 3 shows that 14 of the 16 effects were reported by the majority of respondents, most 
commonly: ‘Drowsiness, feeling tired, sedation’ (92.5%) and ‘Loss of motivation’ (85.8%). 
Nine of the effects were reported as ‘severe’ by over a third of participants, most commonly: 
‘Drowsiness, feeling tired, sedation’ (49.1%) and ‘Weight gain’ (45.3%). 
 
Table 3 about here 
 
      The mean Total Adverse Effects (TAE) score was 24.8 (sd = 10.7). There were no 
differences in TAE score, or any of the 16 adverse effects, between those who had only taken 
antipsychotics and those who had also taken antidepressants.   
      Gender was unrelated to TAE. There was only one specific difference; men produced a 
higher mean for High blood pressure (0.9) than women (0.5) (t = 4.05, df 332.3, p < .001). 
Nearly half the men (46.6%) reported high blood pressure, compared to 30.0% of the women. 
      Age was positively correlated with TAE (rho = .13, p < .01), and with six specific effects 
(p < .01 level or beyond; see Table 3), most strongly (p < .001) with Loss of sex drive, Dry 
mouth, Weight gain and Emotional numbing.  
      Length of time taking antipsychotics was positively correlated with TAE (rho = .18, p < 
.001). Duration was significantly correlated with seven adverse effects (p < .01 level or 
beyond: see Table 3), most strongly (p < .001) Weight gain, Increased Appetite, Withdrawal 
symptoms and Loss of sex drive. 
 
3.3.1 Suicidality 
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‘Suicidality’ was reported to be ‘a side effect of taking antipsychotic medication’ by 
58.3% of participants, with 21.1% ticking ‘severe’. Suicidality was not significantly related to 
gender or age. It was negatively correlated with all three efficacy measures (at the p < .001 
level). The specific adverse effects most strongly correlated with Suicidality (all p < .001) 
were: Feeling not like self (rho = .46), Loss of motivation (.43), Difficulty concentrating 
(.40); Withdrawal effects (.40); Emotional numbing (.37) and Loss of sex drive (.35).  
 
3.3.2. Withdrawal effects 
    ‘Withdrawal effects’ were reported to be a side-effect by 65.2% of respondents, with 
33.2% reporting these to be ‘severe’. ‘Withdrawal effects’ was correlated with length of time 
taking the medication (rho = .19; p < .001). For example, 19.0% of those on the drugs for 
three to six months reported severe withdrawal effects, compared to 42.9% of those who had 
been taking them for more than three years. 
 
3.3.3. ‘Other’ Adverse Effects 
Besides the responses to the 16 listed effects, 331 people wrote in the ‘other’ box. Table 4 
lists the side effects reported by five or more people.  
 
Table 4 about here  
 
     Of the 19 who reported new or increased psychotic symptoms, 13 reported symptoms 
other than those reported in response to ‘What experiences were you having that led you to 
being prescribed antipsychotic medication?’, indicating the creation of psychosis by the 
antipsychotics. Examples of writings in the ‘other’ side effects box follow: 
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A feeling of being utterly stripped of any sense of myself   
 
They killed my creativity, my brain felt wrapped in cotton matting; I was living a half 
life.   
 
I could not feel my spirit/personality.  
 
Increased saliva, depression, anxiety, increased loss of feeling connection with other 
people, loss of creativity to speak or write   
 
Creativity gone, humor gone, memory gone, sexual drive gone, happyness and 
pleasure in life gone 
 
3.4 Reasons for Stopping Antipsychotics 
Of the 613 who responded ‘yes’ to ‘Have you ever thought about stopping your 
antipsychotic medication’, the most frequently endorsed of the ‘reasons for wanting to stop’ 
were ‘Medication caused unpleasant side effects’ - 395 (64.4%) (see Table 5). 
 
Table 5 about here 
 
3.5 Medication Types 
 The 652 who named their ‘current or most recent antipsychotic medication’ cited 24 
antipsychotics, most frequently quetiapine (232 - 35.6%), followed by: olanzapine (101 - 
15.5%); aripiprazole (181 - 12.4%); risperidone (75 - 11.5%) and haloperidol (22 - 3.4%). 
Comparisons were made only on the four with 75 or more cases. The majority (596; 91.4%) 
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were second generation ‘atypical’ antipsychotics and 56 (8.6%) were first generation ‘typical’ 
antipsychotics.  
 
3.5.1 Efficacy 
There was no significant difference between the four antipsychotics in terms of their 
effects on the problems for which they had been prescribed. Olanzapine was, however, less 
‘helpful’, on average (X = 3.49), than quetiapine (X = 2.97); t = 2.88, df 330, p < .01. 
Olanzapine also had a more negative effect on Quality of Life (X = 3.80), than both 
quetiapine (X = 3.27; t = 3.006, df 211.6, p < .01) and aripiprazole (X = 3.25; t = 2.47, df 
158.2, p < .05). There were no differences between first and second generation drugs on the 
three efficacy variables. 
 
3.5.2 Adverse Effects 
The only difference between the four drugs in terms of TAE was that olanzapine (X = 
27.25) scored higher than quetiapine (X = 23.30); t = 3.07, df 301, p < .01. Table 2 shows 
that this was also the case for six specific effects, and that aripiprazole scored worse than 
quetiapine on three effects.   
      First and second generation drugs did not differ on TAE. The atypicals produced a higher 
mean than the typicals for Diabetes and High Blood Pressure. 
 
3.6. Information about Adverse Effects 
     Of the 787 who answered ‘Did the doctor inform you of any possible side effects?’ 239 
(30.4%) replied ‘Yes’ and 548 (69.6%) ‘No’. Those who reported being informed were 
younger (X = 40.1 years) than those who were not told (44.1 years); t = 3.98, df 780, p < 
.001. There was no gender difference.  
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      Those who were not informed scored significantly higher on the TAE scale (X = 25.98) 
than those who were informed (X = 22.15) (t = 4.35; df 680; p < .001). Those who were not 
told reported significantly worse outcomes on each of the three efficacy measures, all at the p 
< .001 level. For example 51.1% of those were told about side effects found antipsychotics 
‘helpful’, compared to 36.6% of those who were not told (X2 = 23.9, p < .001). 
      The side effects that at least five people report being informed about are listed in Table 6, 
most frequently Weight gain (130; 16.0%) and Drowsiness/sedation/tiredness (77; 9.5%). 
Less than 3% of respondents recall being told about any of the other effects.    
 
Table 6 about here 
 
      Examples of what people remember being told include: 
 
All the side effects across the board were attributed to my "illness" called 
"schizophrenia" and I believed them. 
 
I only remember being told that any side effects would be temporary. I was 
discouraged from showing any concern for side effects. 
 
What I do remember is many psychiatrists saying that I would need to accept 
whatever side-effects arose, because my mental health should supersede any physical 
complaints. 
 
Doctors have actually actively attempted to keep me from getting this info but nurses 
will go behind them and do it. 
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4. DISCUSSION 
4.1 Efficacy 
     It is notable that on two measures (Helpfulness and Quality of life) more people reported 
negative than positive outcomes. These rather general measures may be influenced by 
adverse effects and are therefore not pure measures of efficacy in the traditional sense. The 
question that focussed exclusively on symptom reduction produced a better result. The 
majority (55.9%) reported that the drugs reduced the specific problems for which they were 
prescribed. This figure is higher than that produced by most traditional drug trials. In the 
review of 38 clinical trials5, only 41% of the AP recipients were classified as ‘responders’. 
      Nevertheless, it is important to note that 26.9% reported that the problems for which the 
drugs were prescribed were made worse. A two to one ratio between effective and no 
difference might be acceptable. A two to one ratio between being made better and being 
made worse represents an unsatisfactory cost-benefit ratio.  
   
4.2 Adverse Effects 
     The high frequency of 14 adverse effects (reported by 57% or more), and the fact that nine 
were described as ‘severe’ by at least one in three people, is of concern.  
 
4.2.1 Sedation 
     The five most commonly reported effects could all be characterised as the slowing, or 
closing down, of  emotion and cognition, namely ‘Drowsiness, feeling tired, sedation’ ‘Loss 
of motivation’, ‘Slowed thoughts’, ‘Emotional numbing’ and ‘Difficulty concentrating’. 
These five effects were reported by between 85% and 92% of respondents, and were 
described as ‘severe’ by between 36% and 49%. In previous studies sedation, reduced 
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concentration, and emotional flattening have consistently been among the most reported 
effects [27, 37, 38].  For example, the most frequently reported effect in the large website 
study was: ‘Sedative effects (increased sleep, daytime drowsiness, fatigue, lethargy, difficulty 
waking)’ [32].  A smaller survey found that 78% reported Tiredness and 66% had 
Concentration problems [24].  Feeling tired was the most frequently reported effect (77%) in 
the recently developed Maudsley Side Effects measure [31]. Sedation was reported by the 
same percentage (77%) in the development of the My Medicines and Me questionnaire [30].  
      The original descriptor of ‘major tranquillisers’ used in the early years of AP prescribing, 
might be a more accurate name than ‘antipsychotics’. It has been suggested [32, 39] that the 
sedating, tranquillising, closing down, or ‘psychic indifference’ [40] accounts, at least partly, 
for perceived therapeutic effects, via reduced responsiveness to symptoms (and to adverse 
life events) rather than actual reduction in symptoms as traditionally claimed.  
 
4.2.2. Suicidality 
     It is typically assumed that the very high rates of suicide among people diagnosed with 
‘schizophrenia’ spectrum disorders are due to their mental health problems. Although suicide 
as a result of taking antidepressants has recently been established [33, 41], little attention has 
been paid to antipsychotics in this regard. People diagnosed with ‘schizophrenia’ live 
between ten and twenty years less than other people, and the negative medical/biological 
effects of antipsychotics contribute [14, 15]. Although the very high suicide rate clearly also 
contributes to the reduced life span, it is not known how much of that suicidality is caused, 
directly or indirectly, by the antipsychotics, because suicide is never included as a side effect 
in traditional studies [12].  
      To our knowledge no check lists or measures of adverse effects for Antipsychotics ask 
about suicidality. The 2009 website analysis [32] found that 3% of the comments 
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spontaneously reported antipsychotic-induced suicidal thoughts (rising to 14% among those 
experiencing the side effect akathisia). In the current study, the largest first person survey to 
date, and the first questionnaire to directly ask about suicidality, 58% reported suicidality as a 
result of taking antipsychotics. One in five (21%) reported ‘severe’ suicidality.  
      The proportion reporting suicidality goes up to 74% amongst those who thought the drugs 
had made no difference or had made their problems worse. Perhaps whatever degree of 
suicidality is generated by the adverse effects of antipsychotics, the discovery that the drugs 
do not work, or even make things worse, could further increase depression, hopelessness and 
suicidality. These results suggest that all future studies and checklists should include 
suicidality as a potential side effect.  
 
4.2.3 Withdrawal 
     The withdrawal effects experienced when stopping or reducing of antipsychotics has not 
received the attention it warrants. The finding that 65% of the current sample reported 
‘withdrawal effects’ (self-defined) is similar to a recent finding that 65 of 105 (62%) people 
trying to come off antipsychotics experienced withdrawal effects [20]. Withdrawal effects 
can, and should, be distinguished from relapse of the pre-existing psychosis symptoms [42], 
so that people can receive the acknowledgement and support they need to gradually come off 
if they wish to do so [20-22, 42]. 
 
4.3 Age 
     Older people found the drugs less helpful and reported an even worse effect on their 
Quality of Life than younger people. They also reported more adverse effects, including Loss 
of sex drive and Emotional numbing. Other studies have found particularly high rates of 
adverse effects in older people [43]. Paradoxically, older people were particularly unlikely to 
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be told about adverse effects. These findings should be considered in the context of steadily 
increasing use of antipsychotics with older people, with or without psychosis, in recent years. 
 
4.4. Information 
     The finding that less than one in three (30%) recall being told anything about adverse 
effects suggests that most prescribers of antipsychotics may be breaching the ethical principle 
of informed consent. The largest survey of AD users to date found that 64% recalled being 
told something about their side effects [33]. This is not the first study to find that clinicians 
are particularly reluctant to inform patients about the effects of antipsychotics [24, 28, 29].  
This may be for fear that a fully informed patient might wrongly attribute unrelated 
symptoms to the drugs. Prescribers may also fear that an informed patient may be less likely 
to take the medication and that this would negatively influence outcomes. Psychiatrists may 
be reassured to learn that participants who were informed of adverse effects reported fewer 
adverse effects and better outcomes. 
 
4.6 Limitations 
     A limitation of this study is that it uses a convenience sample not a randomised one. 
Therefore the poor outcomes and high rates of adverse effects may be the result of people 
who were dissatisfied with their antipsychotics being more likely to participate. The rates of 
many of the adverse effects are indeed higher than in other studies. For example, previous 
surveys found rates for Weight gain of 40% [32], 50% [24], 53%, [30] and 70% [31], 
compared to 84% in the current study. We have already seen, however, that if there was a 
bias in our sample it was towards participants with relatively positive views about efficacy, 
because more participants reported a positive effect on their symptoms than in drug trials. 
Furthermore, even among participants who felt the drugs had reduced their symptoms, rates 
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of adverse events remained high, e.g. ‘Drowsiness, tiredness, sedation’ - 91%; Slowed 
thoughts - 83%. Nevertheless, large scale randomised surveys are desirable.  
The fact that it was an online survey may mean that very poor people may be 
underrepresented because of lack of internet access. Particularly disturbed people may also be 
under represented, because of difficulty using, or lack of interest in, the internet. 
      Another limitation is that the data was self-reported. It has been established, however, that 
people can reliably report the adverse effects of antipsychotics [19, 46, 47]. It has also been 
shown that self-reported adverse effects are not related to severity of psychosis [31]. 
      Some of the adverse effects may not have been related to the antipsychotics. One study, 
however, found that patients frequently fail to attribute adverse drug effects to antipsychotics 
[24]. It is also possible that some of the positive outcomes may have resulted from life 
changes, or spontaneous remission. 
 
5. CONCLUSIONS 
     This study confirms many previous findings, using various methodologies, that although 
some people benefit from antipsychotics, many, perhaps most, do not [5-9]. The study also 
found that many (27% - 54%) report that the drugs make them worse. Meanwhile, the 
majority experience a range of adverse effects some of which are physically dangerous and 
emotionally numbing or depressing. These drugs should therefore be used with caution, 
probably only after safer and more effective approaches [8, 46, 47] have been tried. 
Furthermore, doctors must adhere to the principle of informed consent. 
      Screening for adverse effects in psychiatric services usually relies on general questioning 
and observation, leading to underestimation [48, 49]. The checklists that are sometimes used 
include a limited range of effects [12]. The 53 item Maudsley Side Effects measure [31], 
generated in consultation with antipsychotic recipients, and demonstrated to have sound 
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psychometric properties, could be a way forward. 
      The experiences of our 832 respondents reinforce a British Journal of Psychiatry 
Editorial, entitled ‘Antipsychotics: Is it time to introduce patient choice?’: 
 
In the context of emerging evidence regarding the overestimation of the effectiveness 
of antipsychotics and the underestimation of their toxicity, as well as emerging data 
regarding the possibility of alternative treatments, it may be time to reconsider the 
prevailing opinion that all service users with psychosis require antipsychotic 
medication in order to recover [50]. 
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Table 1  Sample characteristics of 832 respondents 
 
Gender  male 
 28.0% 
female 
 72.0% 
   
Age mean = 43.1 
 (sd 13.1) 
    
Employment employed  
45.7% 
unemployed 
23.4% 
student 
9.0% 
disabled 
7.1% 
retired  
7.1% 
Ethnicity 
(self-defined) 
white/caucasian  
54.9% 
Australian 
13.7% 
European 
10.0% 
British 
 6.3% 
 
Country* USA 
 25.1% 
Australia 
 24.8% 
UK 
 21.6% 
Canada 
 4.2% 
New Zealand 
3.6% 
 Netherlands 
3.2% 
Ireland 
2.9% 
Denmark 
2.5% 
Germany 
2.0% 
Norway  
1.9% 
 Switzerland 
1.4% 
South Africa 
1.2% 
   
Time on 
antipsychotics 
< 3 months  
7.2% 
3-12 Months 
19.2% 
1-3 years 
18.7% 
>3 years 
54.9% 
 
Current status still taking  
43.6% 
stopped taking 
56.4% 
   
Medication 
type 
only 
antipsychotics 
19.4% 
antipsychotics +  
antidepressants 
80.6% 
   
Most common 
diagnoses 
schizophrenia 
spectrum 
28.0% 
bipolar  
disorder  
24.9% 
depression  
 
24.3%. 
  
 
* Countries with less than 1%: Austria, Belgium, Croatia, Estonia, Finland, France, Greece, 
Iceland, India, Italy, Israel, Lithuania, Poland, Portugal, Romania, Spain, Sweden, Ukraine. 
 
 
 
Table 2    Perceived efficacy of antipsychotic medication  
‘How helpful 
was the AP 
medication?’ 
 
Very 
helpful 
 
Somewhat 
helpful 
 
 
Unsure 
 
Somewhat 
unhelpful 
 
Very 
unhelpful 
Negative 
Outcomes 
Related to…. 
(n = 758) 16.1% 24.8% 16.4% 7.7% 35.1% age * 
 
‘The problems 
for which the 
AP was 
prescribed 
were…’ 
 
 
Greatly 
reduced 
 
 
Slightly 
reduced 
 
 
 
Unchanged 
 
 
Slightly 
worse 
 
 
A lot 
worse 
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(n = 755) 23.8% 32.1% 17.6% 6.2% 20.3%  
‘As a result of 
AP my quality 
of life was…’ 
 
Greatly 
improved 
 
Slightly 
improved 
 
 
Unchanged 
 
Slightly 
worse 
 
A lot 
worse 
 
(N= 759) 14.9% 20.6% 10.8% 12.1% 41.6% age ** 
 
* = p < .05; ** = p < .01 
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Table 3   Responses to ‘What were the side effects of taking antipsychotic medication for 
you?’; and related variables 
 Any Mild Moderate Severe Meana Related to… 
Drowsiness, tiredness, 
sedation 
92.5% 14.0% 29.4% 49.1% 2.20  
Loss of motivation 85.8% 19.4% 22.8% 43.6% 1.96 age** 
duration*** 
aripiprazoleb ** 
olanzapineb** 
Slowed thoughts 
 
85.5% 20.3% 28.7% 36.5% 1.87 olanzapineb *** 
Difficulty concentrating 
 
84.9% 18.3% 27.2% 39.4% 1.91  
Emotional numbing 84.8% 16.2% 26.4% 42.2% 1.96 age***  
olanzapineb *** 
Weight gain 83.5% 14.7% 23.5% 45.3% 1.98 age*** 
duration*** 
aripiprazoleb *** 
olanzapineb *** 
Feeling not like myself 
 
82.7% 15.3% 22.9% 44.5% 1.95 age** 
olanzapineb ** 
Increased appetite 79.5% 16.6% 26.2% 36.6% 1.79 duration*** 
aripiprazoleb  ** 
olanzapineb ** 
Loss of sex drive 74.0% 13.6% 23.8% 36.6% 1.71 age*** 
duration*** 
Dry mouth 72.5% 16.8% 26.2% 26.5% 1.52 age*** 
duration*** 
Withdrawal effects 65.2% 13.9% 18.1% 33.2% 1.50 duration*** 
 
Dizziness 
 
65.4% 27.5% 23.0% 14.9% 1.18  
Suicidality 
 
58.3% 15.6% 21.6% 21.1% 1.22  
Tremors 
 
57.6% 20.1% 19.6% 17.9% 1.13 duration** 
High blood pressure 34.7% 14.6% 13.9% 6.2% 0.61 men*** 
atypicalsc *** 
Diabetes 18.1% 6.1% 8.0% 4.0% 0.34 atypicalsc *** 
 
N ranged from 679 to 692 
a:  ‘did not experience’ = 0; ‘mild’ = 1; ‘moderate’ = 2; ‘severe’ = 3 
b: higher mean score than quetiapine 
c: higher mean than typicals combined 
** = p < .01; *** = p < .001 
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Table 4   Other side effects reported by five or more participants 
Akasthesia/Restlessness 40 Memory Dysfunction 10 
New/Increased Psychosis 19 Increased Anxiety 10 
Tardive Dyskinesia 19 Tachycardia/Palpitations 9 
Lactation (in women) 17 Reduced Coordination 8 
Sleep Problems 16 Reduced Creativity 7 
Aggression/Agitation 16 Seizures/Epilepsy 6 
Dystonia/Muscle spasms 16 Excessive Sweating 5 
Eyesight problems 14 Feeling Like ‘Zombie’ 5 
 
Table 5   Reasons for wanting to stop, of the 613 who had thought about stopping 
Medication caused unpleasant side effects 395 (64.4%) 
I worried about the long-term effect on my physical health 318 (51.9%) 
I wanted to solve the problem without medication 268 (42.4%) 
The medication was not helping 249 (40.6%) 
I felt better and thought I didn’t need the medication  195 (31.8%) 
I was afraid I would get dependent on the medication 105 (17.1%) 
I was worried about stigma associated with medication use 79 (12.9%) 
I don’t remember 28 (4.6%) 
 
Table 6    How many of 814 people were told about specific side effects  
Weight gain 130 Diabetes 6 
Drowsiness/Sedation/Tiredness 77 Increased appetite  6 
Dry mouth 21 Sexual dysfunction 6 
Tardive Dyskinesia 19 Reduced concentration 6 
Dizziness 13 Constipation 6 
Muscle tightness/spasms 10 High cholesterol 5 
Tremors 8 Low blood pressure 5 
Rash 8 Slowed thoughts 5 
Unusual movements 8 Nausea 5 
Akathesia/restlessness 7 Increased anxiety 5 
Suicidality 7 Extrapyramidal symptoms 5 
 
